Helicobacter Pylori Case Studies

The causes of campylobacter are undercooked meats. The food source of campylobacter are raw poultry. You can prevent yourself and others from receiving campylobacter by thoroughly cooking raw food, using a thermometer to be sure that the internal temperature reaches the necessary degree. One fact that you may not know about campylobacter is that the campylobacter species is spiral shaped.

According to Epocrates, the drug of choice would be amoxicillin (Amoxil), which is in the penicillin family. If failed treatment occurs, a higher dosage of amoxicillin should be prescribed or the drug should be changed to amoxicillin/clavulanate (Augmentin). This should be tried before changing to a different drug class (Epocrates, 2014).

Other treatments that could be order are Clarithromycin 500mg twice daily for five days or Clarithromycin XL 1000 mg (Two 500 mg tablets) daily for five days (File, 2017).

Commonly prescribed antibiotics used to treat H. pylori infection include amoxicillin (Amoxil, Trimox), clarithromycin (Biaxin), metronidazole (Flagyl), and tetracycline (Sumycin). This combination of medicines is taken for 10 to 14 days. It is important for patients to take the full course of medications exactly as directed. An improvement in symptoms does not necessarily mean that H. pylori bacteria are no longer present (O'Connor, Vaira, Gisbert, & O'Morain, 2014).

Treat with Amoxicillin 875 mg BID or Amoxicillin 500 mg TID x 5-7 days. Instruct client to take the medication as directed, and to complete all doses even if symptoms improve (Natal,

Contraindications for ceftazidime include patients with cephalosporin or cephamycin hypersensitivity. In patients with penicillin hypersensitivity, caution should be exercised when administering this drug. Cross-reactivity can occur due to the similar structures or penicillin and ceftazidime. Cross-reactivity has been documented in approximately 3-7% of patients with a history of penicillin hypersensitivity. Allergic reaction can range from mild to fatal, and those with severe reactions to penicillin should not be given this drug. Discontinue the use of ceftazidime if an allergic reaction occurs (6). Pseudomembranous colitis has been associated with all antibacterial agents, including ceftazidime, and may be life-threatening. The administration of an antibacterial causes changes in the normal flora in the colon, and may allow overgrowth of Clostridia. Toxins produced by Clostridium difficile has been identified as the primary cause of antibacterial-associated colitis. Caution should be taken when administering ceftazidime in patients with a history of GI disease. If a patient presents diarrhea after treatment with antibiotics, then a diagnoses of pseudomembranous colitis should be considered. Discontinue the use of ceftazidime if diarrhea occurs (6). Another rare adverse effect includes a decrease in prothrombin activity. This may cause bleeding and should be administered with caution in patients with a diagnosed coagulopathy. Ceftazidime must be used with

In 1970’s researches demonstrated 21% of patients treated with antibiotic clindamycin (Cleocin) reported diarrhea; 10% of the study population developed pseudomembranous colitis as a consequence of this treatment (). By the later 1970’s, C. diff had been recognized as the infectious cause of antibiotic-associated diarrhea and colitis ().

It also helps with the prevention of PCP in HIV-positive patients, but should be used cautiously due to the incidence of adverse reactions. This drug is also active against many strains of gram-positive pathogens including: Streptococcus pneumoniae, Staphylococcus aureus, Group A beta-hemolytic streptococci, Nocardia, Enterococcus. It also has activity against many gram-negative pathogens, such as: Acinetobacter, Enterobacter, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Shigella, Xanthomonas maltophilia, and Haemophilus influenzae, including ampicillin-resistant

Triple therapy with metronidazole and either bismuth subsalicylate or bismuth subcitrate plus either amoxicillin or tetracycline for 14 days eradicates H pylori infection in 70–95% of patients. An acid-suppressing agent given for 4–6 weeks enhances ulcer healing. Proton pump inhibitors (such as omeprazole) directly inhibit H pylori and appear to be potent urease inhibitors. Either 1 week of a proton pump inhibitor plus amoxicillin and clarithromycin or of amoxicillin plus metronidazole also is highly effective [51].

Selective use of antibiotics to control outbreaks 
Note: Routine use of oral and systemic antibiotics was considered but not recommended.

Hello Kelli, I enjoyed reading your post. You made some good points. I just want to add to what your mention about H. pylori being treated with two varieties of antibiotics the patient may also be given proton pump inhibitor, histamine receptor blocker, and protectants to help relieve pain. I think it is interesting o how the breath test is performed and thanks for sharing that information because it very helpful. It is also important that patient doesn’t eat or drink anything for a least 6 hours before the breath or stomach biopsy is performed. Other than those small adjustments that I wanted to add, I think you did a wonderful job.

S: MM is not contraindicated to taking clindamycin. Clindamycin generally has more serious side effects than amoxicillin including colitis and more severe diarrhea (8). This is another reason why amoxicillin is preferred for

Some control strategies are medications if you have ulcers caused by H. Pylori, you need to treat the ulcers from coming back. Most common way is antibiotics to kill the bacteria, such as, metronidazole. Also you can take a drug that reduces the amount of acid in your stomach such as omeprazole. Also you can protect yourself from h. Pylori the same way you would protect your self form any other bacteria, wash your hand and avoid unclean food and water.

pylori eradication rates. Several studies have been published that tested this approach, including this paper by Calvet et al. These authors studied the value of extending PPI-based triple therapy from 7 to 10 days and found no additional benefit for patients with peptic ulcers. There was, however, a significant benefit for nonulcer dyspepsia patients (an increase from 66% to 77% in the intention-to-treat analysis and from 73% to 91% in the per-protocol analysis). The authors concluded that the treatment period should be extended from 7 to 10 days for patients with nonulcer dyspepsia. As most eradication therapy, however, is given to patients with uninvestigated dyspepsia, it is not unreasonable to argue that longer therapy should be given to all subjects. Distinguishing between patients with ulcer and nonulcer dyspepsia is therefore rather academic and impractical. The most obvious one is that existing PPI-based triple therapy regimens are not perfect. In the community at large, up to 30% of patients might fail this therapy. If clinicians prescribe triple therapy it should therefore be prescribed for longer than 7 days. This runs the risk of decreased patient compliance, more side effects and a greater cost, but ultimately it boils down to local and national guidelines, which vary from one country to another. Alternatively, clinicians might consider some of the newer eradication approaches, such

Clindamycin could be used for patient A as it is effective against penicillin-resistant staphylococci, organism A was found to be resistant to penicillin in this experiment. Clindamycin is recommended for skin and soft tissue infections and can be prescribed to young children. The dosage recommended for patient A is 3-6mg/kg per dose 4 times a day, orally.